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Abstract
Introduction
Dapagliflozin is a member of a novel class of drugs (sodium-glucose cotransporter-2 inhibitors)
used to treat type 2 diabetes mellitus and licensed in Pakistan in 2017. This retrospective
observational study evaluated the effects of dapagliflozin on glycated hemoglobin (HbA1c)
concentrations in patients treated at endocrinology clinics in Islamabad, Pakistan. The
secondary objectives included assessing the effects of dapagliflozin on weight reduction and
blood pressure control and to determining its safety.
Methodology
Patients with type 2 diabetes who were treated with dapagliflozin were identified by screening
the electronic medical records at tertiary care hospitals in Islamabad. Data were collected at the
first visit and at follow-up. Categorical variables were recorded as frequencies and percentages
and compared by McNemar’s tests, and continuous variables were recorded as means and
standard deviations and compared by paired sample t-tests.
Results
Mean HbA1C concentration was significantly lower at follow-up than at the first visit
(7.57%±0.98% vs. 9.07%±2.07%, respectively; p<0.001). Bodyweight (85.09±15.92 kg vs.
87.07±16.11 kg, respectively; p<0.001) and diastolic blood pressure (80.34±7.12 mmHg vs.
82.34±9.61 mmHg, respectively; p<0.001) were also significantly lower at follow-up than at the
first visit, whereas systolic pressure showed a marginally significant reduction (123.5±16.57
mmHg vs. 126.83±19.97 mmHg, p=0.048).
Conclusion
This first observational study of patients in Pakistan treated with dapagliflozin found that
HbA1c concentration, weight, and blood pressure were reduced after initiation of dapagliflozin
treatment.
Categories: Endocrinology/Diabetes/Metabolism
Keywords: type 2 diabetes mellitus, dapagliflozin, retrospective study, hemoglobin a1c
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Introduction
Pakistan currently ranks fourth in the world in the percentage of people with diabetes mellitus,
with an estimated prevalence of 26.3% [1]. Effective therapeutic agents are, therefore, needed
to manage diabetes as well as to prevent diabetes-associated microvascular and macrovascular
complications [2]. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a novel class of drugs
effective in managing type 2 diabetes mellitus, both as monotherapy and combined with other
agents [3]. One member of this class, dapagliflozin, is a highly selective, potent SGLT2i, first
licensed for use in Pakistan in 2017 [4,5].
Several studies have evaluated and confirmed the safety and efficacy of dapagliflozin in real-
life clinical settings. Pakistani populations differ in genetic characteristics, as well as in
demographic, cultural, and lifestyle characteristics, from the populations of Western countries
[6-10]. This retrospective, real-life observational study evaluated the effectiveness and safety of
dapagliflozin 10 and 5 mg once daily combined with other agents in Pakistani patients.
Materials And Methods
This retrospective observational study involved patients evaluated at endocrinology clinics of
Shifa International Hospital and Umar Diabetes and Foot Care Centre in Islamabad, Pakistan.
The study was conducted after approval by Ethical Review Committee. All patients with type 2
diabetes, who were treated with dapagliflozin, were identified by screening electronic medical
records at these hospitals. Patients were included if they had been diagnosed with type 2
diabetes for at least six months and were treated with dapagliflozin as monotherapy or
combined with one or two other oral agents or insulin. Patients were excluded if they had type
1 diabetes, a glomerular filtration rate (GFR) <45 ml / min / 1.73 m2, or a history of recurrent
genitourinary tract infections. Patients were also excluded if they were taking this drug for
weight loss, or if data were missing from their medical records.
Data were collected at the first visit and at follow-up. The date of the first prescription of
dapagliflozin was defined as the medication index date. The baseline period was defined as two
to three months before the medication index date. Based on available information, follow-up
data were retrieved three to six months after the medication index date.
Patient information was collected using a predesigned data collection form. Demographic
characteristics included age and gender, and disease-related characteristics at the first visit
included duration of diabetes, number of comorbidities, microvascular complications (e.g.,
retinopathy based on retinal eye screening, nephropathy based on GFR below 90 ml/min/ 1.73
m2, neuropathy based on symptoms), dyslipidemia, and urinary albumin:creatinine ratio.
Details about other antidiabetic drugs, antihypertensive agents, and lipid-lowering medications
were also recorded at baseline and follow-up, as were clinical parameters, including weight,
systolic blood pressure, diastolic blood pressure, glycated hemoglobin (HbA1c), and serum
creatinine concentrations. For laboratory parameters, the last available measurement during
follow-up (three to six months after medication index date) was compared with baseline
measurements.
The safety of dapagliflozin was assessed by recording adverse effects, the proportion of patients
with adverse effects, and the proportion of patients who discontinued treatment due to side
effects or lack of efficacy.
Statistical analysis
All statistical analyses were performed using IBM SPSS Statistics for Windows, Version 20.0
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(Armonk, NY: IBM Corp.). Categorical variables were recorded as frequencies and percentages
for each category and compared by McNemar’s tests, and continuous variables were recorded as
means and standard deviations and compared by paired t-tests. Predictors of post-dapagliflozin
HbA1c (%) reduction and weight loss (dependent variable) were evaluated using a multivariate
linear regression model. Results are expressed as odds ratios (ORs) and 95% confidence
intervals (CIs). A p-value <0.05 was considered statistically significant.
Results
The study cohort consisted of 412 patients with type 2 diabetes (Figure 1). Table 1 summarizes
their baseline characteristics. The 412 patients included 226 (54.9%) men and 186 (45.1%)
women, with a mean age of 52.6±10.8 years and mean diabetes duration of 9.3±6.2 years. At
baseline, their mean weight was 87.07±16.11 kg, and their mean HbA1c concentration was
9.07%±2.07%. At baseline, 88.3% of patients were being treated with a single antidiabetic agent,
11% were on dual therapy, and 33.7% were being treated with insulin.
Variable Values
Age (years), mean±SD 52.6±10.8
Diabetes duration (years), mean±SD 9.34±6.20
Gender, n (%)  
Male 226 (54.9)
Female 186 (45.1)
HbA1C (%), mean±SD 9.07 (2.07)
Weight (kg), mean±SD 87.07 (16.11)
SBP (mmHg), mean±SD 126.38 (19.97)
DBP (mmHg), mean±SD 82.34 (9.61)
Comorbidity, n (%)  
No 23 (5.6)
Yes 289 (94.4)
No. of comorbidities, mean±SD 2.28±1.28
Hypertension, n (%) 212 (51.5)
Heart diseases, n (%) 47 (11.4)
Dyslipidemia, n (%) 267 (64.8)
No. of concomitant medications, mean±SD 6.33±2.39
No. of antihyperglycemic medications, mean±SD 3.07±0.99
No. of antihypertensive medications, mean±SD 1.08±1.01
Dapagliflozin dose, n (%)  
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5 mg 75 (18.2)
10 mg 337 (81.8)
Antihypertensive drugs, n (%)  
ACE inhibitors 54 (13.1)
Ca-channel blockers 95 (23.1)
Diuretics 50 (12.1)
ARBs 188 (45.6)
Beta blockers 58 (14.1)
Antihyperglycemic drugs, n (%)  
None 3 (0.7)
Monotherapy 364 (88.3)
Dual therapy 45 (11.0)
Insulin 139 (33.7)
Lipid-lowering therapy, n (%)  
Statins 282 (68.4)
Simvastatin 14 (3.4)
Atorvastatin 113 (27.4)
Rosuvastatin 137 (33.3)
Pitavastatin 23 (5.6)
Other lipid-lowering medications, n (%)  
Ezetimibe 22 (5.3)
Fenofibrate 20 (4.8)
TABLE 1: Baseline characteristics of study population
SD, standard deviation; HbA1c, glycated hemoglobin; SBP, systolic blood pressure; DBP, diastolic blood pressure; ACE, angiotensin-
converting enzyme; ARB, angiotensin receptor blocker.
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FIGURE 1: Study flow
Patient flow diagram showing the profile of patients in this trial.
HbA1c, glycated hemoglobin.
Table 2 shows changes in mean clinical outcomes from the baseline (first visit) to follow-up in
these patients. HbA1c concentration was significantly lower at follow-up than at baseline
(7.97%±0.98 vs. 9.07%±2.07, respectively; p<0.001). The proportion of patients who achieved
different levels of HbA1c at baseline and follow-up within six months are presented in Figure 2.
Bodyweight (85.09±15.92 kg vs. 87.07±16.11 kg, p<0.001) and diastolic blood pressure
(80.34±7.12 mmHg vs. 82.34±9.61 mmHg, respectively; p<0.001) were also significantly lower at
follow-up than at baseline, whereas systolic pressure showed a marginally significant reduction
(123.5±16.57 mmHg vs. 126.83±19.97 mmHg, respectively; p=0.048). 
2020 Kamin et al. Cureus 12(6): e8565. DOI 10.7759/cureus.8565 5 of 9
Variable Baseline Follow-up Change P value
Weight (kg) 87.07±16.11 85.09±15.92 -1.98±3.03 <0.001
HbA1C (%) 9.07±2.07 7.97±0.98 -1.1±1.43 <0.001
SBP (mmHg) 126.83±19.97 123.5±16.57 -2.80±15.67 0.048
DBP (mmHg) 82.34±9.61 80.34±7.12 -2.02±7.68 <0.001
TABLE 2: Changes in clinical outcomes from baseline to three to six months after
starting dapagliflozin treatment in patients with type 2 diabetes
HbA1c, glycated hemoglobin; SBP, systolic blood pressure; DBP, diastolic blood pressure.
FIGURE 2: Levels of HbA1c at baseline and follow-up
Numbers of patients achieving various HbA1c levels at baseline and after three to six months
months of treatment with dapagliflozin.
HbA1c, glycated hemoglobin.
Of these patients, 43.7% reported that dapagliflozin had no adverse effects, whereas 27.3%
reported some minor adverse effects, the most frequent being polyuria, urinary tract infections,
and genital infections (Table 3). About 4% developed hypoglycemia, whereas 29% discontinued
treatment due to a lack of efficacy.
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Variable N (%)
None 180 (43.7)
Hypoglycemia 19 (4.6)
Body spasm 2 (0.5)
Fatigue 1 (0.2)
Genital infections 4 (1.0)
Gastrointestinal problems 1 (0.2)
Headaches 1 (0.2)
Joint pains 1 (0.2)
Polyurea 11 (2.7)
Shivering 1 (0.2)
Skin rashes 2 (0.5)
Urinary problems 5 (1.2)
UTI 5 (1.2)
Weakness 1 (0.2)
No benefit 29 (7.0)
TABLE 3: Side effects of dapagliflozin
UTI, urinary tract infection.
Discussion
This retrospective analysis was the first study in Pakistan to assess the safety and efficacy of an
SGLT2i in patients with diabetes mellitus. Dapagliflozin initiation was found to significantly
improve clinical parameters in patients with diabetes in a real-world clinical setting, reducing
HbA1c concentration, weight, and blood pressure, similar to the results of clinical trials. Of the
included patients, 30.8% achieved a target HbA1c ≤7% after starting dapagliflozin. Moreover,
the proportion of patients with HbA1c >9% decreased significantly, from 41.26% (n=170) at
baseline to only 5.58% (n=23) at follow-up. These findings indicated that dapagliflozin-
associated improvement was greater among patients with poor glycemic control, despite the
study cohort being younger and having a longer duration of diabetes than other study cohorts.
One of the benefits of SGLT2 inhibitor treatment in patients with type 2 diabetes mellitus is the
weight loss associated with this class of drugs, a study showed weight loss change versus
placebo was -1.3 to -2.0 kg [11]. In the present study, the mean weight change after
dapagliflozin initiation was -1.98 kg, comparable to findings in a large real-world cohort, which
reported a mean weight change of -2.20 kg after treatment with dapagliflozin for three to six
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months.
Although 27% of the patients in this study experienced side effects of dapagliflozin, only a
small percentage had urinary tract infections and genital infection. This may have been due to
the use of wet hygiene practices in Pakistani populations, resulting in lower rates of urinary
tract and genital infections than those observed in other clinical studies of dapagliflozin [12].
Also, only 4% of the participants in the present study developed hypoglycemia, similar to
previous findings [13]. However, the patients in our study who developed hypoglycemia were
already on insulin or a sulfonylurea, suggesting that hypoglycemia in these patients was not
primarily caused by dapagliflozin.
This study had several limitations, mainly concerning the source of the data. For example, the
interval between HbA1c measurements was not constant. Also, patient records did not mention
whether insulin doses were reduced after they started taking dapagliflozin. Because this study
analyzed patients treated with dapagliflozin for three to six months, it was not possible to
predict therapeutic persistence. Large-scale real-life studies are needed to determine whether
treated with SGLT2is or hygiene practices were responsible for the reduced rates of urinary tract
and genital infections in Pakistani populations. An ongoing open-label randomized controlled
trial is testing the safety and efficacy of another SGLT2i, empagliflozin, in a Pakistani Muslim
population (SAFE-PAK Study).
Conclusions
This retrospective, real-life observational study evaluated the effectiveness and safety of
dapagliflozin in Pakistani patients. Our findings indicate that the SGLT2i dapagliflozin is an
effective agent in treating patients with type 2 diabetes, with good efficacy and safety profiles.
Dapagliflozin use in patients with diabetes is associated with improved glycemic control by
controlled excretion of glucose through the urine and weight loss as a secondary, additional
benefit. Furthermore, it had a positive impact on the cardiovascular dynamics by maintaining
blood pressure. However, dapagliflozin use is associated with a mild risk of urinary tract
infection, albeit lower than what has been previously reported. Dapagliflozin is a useful
treatment option for patients in this cohort with type 2 diabetes.
Additional Information
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hospitals of Pakistan” has been reviewed by the IRB/EC. The IRB & Ethics Committee is pleased
to approve the study. Animal subjects: All authors have confirmed that this study did not
involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform
disclosure form, all authors declare the following: Payment/services info: All authors have
declared that no financial support was received from any organization for the submitted work.
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